Literature DB >> 23306952

Studying complexes between PPI dendrimers and Mant-ATP.

A Szulc1, D Appelhans, B Voit, M Bryszewska, B Klajnert.   

Abstract

The aim of this study was to investigate the interactions between poly(propylene imine) (PPI) dendrimers and 2'-/3'-O-(N'-methylanthraniloyl)-ATP (Mant-ATP). Mant-ATP was used as a model molecule. Purine and pyrimidine nucleoside analogues are antimetabolites commonly used in therapy for cancer. Drug molecules can complex with dendrimers in two ways: therapeutic agents may be attached in dendrimer interior or bind to functional groups on the surface. Drugs attached to nanoparticles are characterized by improved solubility, pharmacokinetics and stability. Here, we have used poly(propylene imine) dendrimers of the 4th and 5th generations (PPI G4 and PPI G5) with primary amino surface groups partially modified with maltose (PPI-m) or without modification (PPI). We assessed the efficiency of complex formation in relation to dendrimer generation, pH of solution and the type of dendrimer used. A double fluorimetric titration method was used to estimate the binding constant (K b ) and the number of binding centers per molecule of the binding agent (n).

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23306952     DOI: 10.1007/s10895-012-1153-y

Source DB:  PubMed          Journal:  J Fluoresc        ISSN: 1053-0509            Impact factor:   2.217


  28 in total

Review 1.  Dendrimers in biomedical applications--reflections on the field.

Authors:  Sönke Svenson; Donald A Tomalia
Journal:  Adv Drug Deliv Rev       Date:  2005-11-21       Impact factor: 15.470

Review 2.  Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.

Authors:  Tadeusz Robak
Journal:  Transfus Apher Sci       Date:  2005-02       Impact factor: 1.764

3.  Influence of surface functionality of poly(propylene imine) dendrimers on protease resistance and propagation of the scrapie prion protein.

Authors:  Marlies Fischer; Dietmar Appelhans; Simona Schwarz; Barbara Klajnert; Maria Bryszewska; Brigitte Voit; Mark Rogers
Journal:  Biomacromolecules       Date:  2010-05-10       Impact factor: 6.988

Review 4.  Pharmaceutical and biomedical potential of surface engineered dendrimers.

Authors:  Jitendra Satija; Umesh Gupta; Narendra Kumar Jain
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2007       Impact factor: 4.889

Review 5.  Therapeutic and diagnostic applications of dendrimers for cancer treatment.

Authors:  Jesse B Wolinsky; Mark W Grinstaff
Journal:  Adv Drug Deliv Rev       Date:  2008-03-04       Impact factor: 15.470

6.  Interactions between PAMAM dendrimers and bovine serum albumin.

Authors:  Barbara Klajnert; Lidia Stanisławska; Maria Bryszewska; Bartłomiej Pałecz
Journal:  Biochim Biophys Acta       Date:  2003-05-30

Review 7.  Review of recent studies on resistance to cytotoxic deoxynucleoside analogues.

Authors:  Lars Petter Jordheim; Charles Dumontet
Journal:  Biochim Biophys Acta       Date:  2007-08-14

8.  A novel phenotypic method to determine fludarabine triphosphate accumulation in T-lymphocytes from hematopoietic cell transplantation patients.

Authors:  Erica L Woodahl; Joanne Wang; Shelly Heimfeld; Brenda M Sandmaier; Paul V O'Donnell; Brian Phillips; Linda Risler; David K Blough; Jeannine S McCune
Journal:  Cancer Chemother Pharmacol       Date:  2008-04-09       Impact factor: 3.333

9.  Binding properties of water-soluble carbosilane dendrimers.

Authors:  Elzbieta Pedziwiatr; Dzmitry Shcharbin; Louis Chonco; Paula Ortega; F Javier de la Mata; Rafael Gómez; Barbara Klajnert; Maria Bryszewska; Ma Angeles Muñoz-Fernandez
Journal:  J Fluoresc       Date:  2008-08-30       Impact factor: 2.217

10.  Hyperbranched PEI with various oligosaccharide architectures: synthesis, characterization, ATP complexation, and cellular uptake properties.

Authors:  Dietmar Appelhans; Hartmut Komber; Mohiuddin Abdul Quadir; Sven Richter; Simona Schwarz; Jereon van der Vlist; Achim Aigner; Martin Müller; Katja Loos; Jürgen Seidel; Karl-Friedrich Arndt; Rainer Haag; Brigitte Voit
Journal:  Biomacromolecules       Date:  2009-05-11       Impact factor: 6.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.